Skip to main content
Full access
Letter
Published Online: 1 January 2002

Treatment of ADHD When Tolerance to Methylphenidate Develops

To the Editor: We have been distressed over the years by the number of older children and adolescents referred to us with the sequelae of untreated attention-deficit hyperactivity disorder (ADHD): school failure, social ostracism, family alienation, low self-esteem, and sometimes drug abuse and delinquency. Their history often included treatment with methylphenidate or dextroamphetamine that was effective for a while but then became ineffective. In treating these patients, we found that higher dosages were effective and that years of treatment had thus been lost. Sometimes the larger dosages were in excess of 60 mg of methylphenidate or 40 mg of dextroamphetamine a day, the highest recommended in the Physicians' Desk Referenceand the Canadian Compendium of Pharmaceuticals and Specialties. Many physicians would be hesitant to prescribe such large dosages.
Others have noticed this phenomenon. In 1973 Wender (1) wrote, "The principles of medication of stimulant drugs are analogous to those employed with digitalis. One should begin with the lowest expectable effective dose and increase the agent until either an optimal response is reached or side effects become troublesome."
An effective dosage cannot be calculated on the basis of weight alone. The symptoms of heavy children can sometimes be controlled with low dosages, and some light children may need high dosages. Biochemical geneticists have focused on a new area of research, genetic predisposition, which is concerned with how genetic factors can account for variations in individual sensitivity to a drug (2).
To quantify our impressions, we decided to examine the charts of a number of patients treated with methylphenidate between 1976 and 1990. If tolerance to methylphenidate developed, children were treated with dextroamphetamine. The sample consisted of 166 children and adolescents with a DSM-III diagnosis of ADHD—117 males and 49 females—who were treated at a practice in Windsor, Ontario, and whose charts were selected randomly from an alphabetical list. Most were of British or French ancestry, and most were from blue-collar families (Hollingshead's class 4) (3).
Of the 166 patients, 68 (41 percent) required more than 60 mg of methylphenidate a day, either initially or later in treatment. Among the 68 patients, 36 (52 percent) developed anorexia, 26 (39 percent) developed insomnia, and 41 (60 percent) developed tolerance to the medication, or failure to maintain a clinical response to the same dosage. Among the 98 patients who were taking less than 60 mg of methylphenidate a day, nine (9 percent) had anorexia, 16 (16 percent) had insomnia, and none developed tolerance. As Winsberg and associates found previously (4), tolerance developed only among children in our sample who were receiving more than 60 mg of methylphenidate or 40 mg of dextroamphetamine a day. For some of our patients, tolerance developed within a few days, and among others it took more than a year.
For patients taking methylphenidate who became tolerant, we tried other drugs, starting with dextroamphetamine, and then we used the drug that produced the best response. If the substitute was less effective than methylphenidate, the latter would be tried again after a month. In many cases, tolerance disappeared after a month, and methylphenidate's original effectiveness was restored. The newfound effectiveness would often last the same amount of time as the original.

Footnote

Dr. Ross is clinical assistant professor of psychiatry and Dr. Fischhoff is professor emeritus of psychiatry in the department of psychiatry and behavioral neurosciences at Wayne State University School of Medicine in Detroit. Dr. Davenport is in private practice in Rutherfordton, North Carolina.

References

1.
Wender PH: Minimal brain dysfunction in children: diagnosis and management. Pediatric Clinics of North America 20:187-202, 1975
2.
West WL, Knight EM, Pradhan S, et al: Interpatient variability: genetic predisposition and other genetic factors. Journal of Clinical Pharmacology 37:635-648, 1997
3.
Hollingshead AB, Redlich FC: Social Class and Mental Illness. New York, Wiley, 1958
4.
Winsberg B, Matinsky S, Kupietz S, et al: Is there dose-dependant tolerance associated with chronic methylphenidate therapy in hyperactive children? Oral dose and plasma considerations. Psychopharmacology Bulletin 23:107-110, 1987

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services
Psychiatric Services
Pages: 102
PubMed: 11773663

History

Published online: 1 January 2002
Published in print: January 2002

Authors

Affiliations

Joseph Fischhoff, M.D.
Barbara Davenport, M.D.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Psychiatric Services

PPV Articles - Psychiatric Services

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share